论文部分内容阅读
目的:观察雷公藤多甙联合小剂量强的松治疗Graves眼病的临床疗效及其安全性。方法:将39例Graves眼病患者随机分为2组,治疗组23例,予雷公藤多甙联合小剂量强的松治疗;对照组16例,予单纯大剂量强的松治疗,疗程16周。结果:2组临床表现疗效比较,差异无显著性意义(P>0.05);2组治疗后突眼度疗效比较,差异无显著性意义(P>0.05);2组治疗后CD4均减少,CD8均增多,CD4/CD8均降低,与治疗前比较,差异均有显著性意义(P<0.05)。2组副作用发生率比较,差异有非常显著性意义(P<0.01)。结论:雷公藤多甙联合小剂量强的松治疗Graves眼病可获得较好的近期疗效,副作用小,安全性明显优于大剂量强的松。
Objective: To observe the clinical efficacy and safety of Tripterygium wilfordii combined with low-dose prednisone in the treatment of Graves ophthalmopathy. Methods: Thirty-nine patients with Graves ophthalmopathy were randomly divided into two groups. Treatment group (23 cases) received tripterygium glycosides combined with low-dose prednisone. Control group (16 cases) received high-dose prednisone for 16 weeks. Results: There was no significant difference in clinical efficacy between the two groups (P> 0.05). There was no significant difference between the two groups (P> 0.05) Both increased, CD4 / CD8 decreased, compared with before treatment, the difference was significant (P <0.05). The incidence of side effects in the two groups, the difference was significant (P <0.01). Conclusion: Tripterygium glycosides combined with low-dose prednisone treatment of Graves ophthalmopathy can obtain better short-term curative effect with less side effects and better safety than prednisone at high dosage.